Catalyst Biosciences (NASDAQ:CBIO) and Odonate Therapeutics (NASDAQ:ODT) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, risk, profitability, institutional ownership, analyst recommendations, earnings and valuation.
Earnings & Valuation
This table compares Catalyst Biosciences and Odonate Therapeutics’ revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Catalyst Biosciences||$1.02 million||104.60||-$21.56 million||($7.45)||-1.20|
|Odonate Therapeutics||N/A||N/A||-$32.74 million||($2.31)||-7.15|
Institutional and Insider Ownership
67.6% of Catalyst Biosciences shares are held by institutional investors. Comparatively, 91.8% of Odonate Therapeutics shares are held by institutional investors. 3.1% of Catalyst Biosciences shares are held by insiders. Comparatively, 49.0% of Odonate Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Risk & Volatility
Catalyst Biosciences has a beta of 2.51, suggesting that its share price is 151% more volatile than the S&P 500. Comparatively, Odonate Therapeutics has a beta of 0.95, suggesting that its share price is 5% less volatile than the S&P 500.
This table compares Catalyst Biosciences and Odonate Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a breakdown of current ratings and recommmendations for Catalyst Biosciences and Odonate Therapeutics, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Catalyst Biosciences presently has a consensus price target of $23.88, suggesting a potential upside of 167.36%. Given Catalyst Biosciences’ higher probable upside, equities analysts clearly believe Catalyst Biosciences is more favorable than Odonate Therapeutics.
Catalyst Biosciences beats Odonate Therapeutics on 8 of the 11 factors compared between the two stocks.
About Catalyst Biosciences
Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing medicines to address hematology indications. Its product pipeline includes marzeptacog alfa, a Factor VIIa variant that is in a Phase II/III clinical trial for the prophylactic treatment of individuals with severe hemophilia A and B with inhibitors. The company is also developing CB 2679d/ISU304, a Factor IX drug, which has completed enrollment of a Phase I/II subcutaneous dosing trial for the prophylactic treatment of individuals with hemophilia B; and CB 2782, an anti-C3 protease program for the treatment of dry age-related macular degeneration (AMD), as well as CB 1965a, a Factor Xa therapeutic program used as a universal procoagulant. Catalyst Biosciences, Inc. has collaboration agreement with Pfizer, Inc. for the development of human Factor VIIa products; and ISU Abxis for development and manufacturing of the Factor IX products through Phase I/II clinical trials. The company has strategic research collaboration with Mosaic Biosciences, Inc. to develop intravitreal anti-complement factor 3 products for the treatment of dry AMD and other retinal diseases. The company is headquartered in South San Francisco, California.
About Odonate Therapeutics
Odonate Therapeutics, Inc., a pharmaceutical company, develops therapeutics for the treatment of cancer. It focuses on the development of tesetaxel, an orally administered chemotherapy agent for patients with advanced or metastatic breast cancer (MBC). Odonate Therapeutics, Inc. also conducting a Phase III study in MBC, which is known as CONTESSA. The company was founded in 2013 and is based in San Diego, California.
Receive News & Ratings for Catalyst Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.